107 related articles for article (PubMed ID: 25985824)
1. Development of a microparticulate prostate cancer vaccine and evaluating the effect of route of administration on its efficacy via the skin.
Akalkotkar A; Chablani L; Tawde SA; D'Souza C; D'Souza MJ
J Microencapsul; 2015; 32(3):281-9. PubMed ID: 25985824
[TBL] [Abstract][Full Text] [Related]
2. Oral delivery of particulate prostate cancer vaccine: in vitro and in vivo evaluation.
Akalkotkar A; Tawde SA; Chablani L; D'Souza MJ
J Drug Target; 2012 May; 20(4):338-46. PubMed ID: 22296308
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery.
Tawde SA; Chablani L; Akalkotkar A; D'Souza MJ
J Control Release; 2016 Aug; 235():147-154. PubMed ID: 27238440
[TBL] [Abstract][Full Text] [Related]
4. Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine.
Parenky AC; Akalkotkar A; Mulla NS; D'Souza MJ
Vaccine; 2019 Sep; 37(41):6085-6092. PubMed ID: 31477437
[TBL] [Abstract][Full Text] [Related]
5. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
6. Formulation and evaluation of oral microparticulate ovarian cancer vaccines.
Tawde SA; Chablani L; Akalkotkar A; D'Souza C; Chiriva-Internati M; Selvaraj P; D'Souza MJ
Vaccine; 2012 Aug; 30(38):5675-81. PubMed ID: 22750042
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a Particulate Breast Cancer Vaccine Delivered via Skin.
Chablani L; Tawde SA; Akalkotkar A; D'Souza MJ
AAPS J; 2019 Jan; 21(2):12. PubMed ID: 30604321
[TBL] [Abstract][Full Text] [Related]
8. A novel microparticulate vaccine for melanoma cancer using transdermal delivery.
Bhowmik T; D'Souza B; Shashidharamurthy R; Oettinger C; Selvaraj P; D'Souza MJ
J Microencapsul; 2011; 28(4):294-300. PubMed ID: 21545320
[TBL] [Abstract][Full Text] [Related]
9. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
[TBL] [Abstract][Full Text] [Related]
11. Oral microparticulate vaccine for melanoma using M-cell targeting.
D'Souza B; Bhowmik T; Shashidharamurthy R; Oettinger C; Selvaraj P; D'Souza M
J Drug Target; 2012 Feb; 20(2):166-73. PubMed ID: 21981679
[TBL] [Abstract][Full Text] [Related]
12. Immunization with a recombinant GnRH vaccine conjugated to heat shock protein 65 inhibits tumor growth in orthotopic prostate cancer mouse model.
Xu J; Zhu Z; Wu J; Liu W; Shen X; Zhang Y; Hu Z; Zhu D; Roque RS; Liu J
Cancer Lett; 2008 Feb; 259(2):240-50. PubMed ID: 18039558
[TBL] [Abstract][Full Text] [Related]
13. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
[TBL] [Abstract][Full Text] [Related]
14. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
[TBL] [Abstract][Full Text] [Related]
15. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
[TBL] [Abstract][Full Text] [Related]
16. Messenger RNA vaccine based on recombinant MS2 virus-like particles against prostate cancer.
Li J; Sun Y; Jia T; Zhang R; Zhang K; Wang L
Int J Cancer; 2014 Apr; 134(7):1683-94. PubMed ID: 24105486
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer vaccines.
Michael A; Relph K; Annels N; Pandha H
Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer.
Kim S; Lee JB; Lee GK; Chang J
Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351
[TBL] [Abstract][Full Text] [Related]
20. Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells.
Schroten C; Scheffer R; Boon L; de Ridder CM; Bangma CH; Kraaij R
J Immunother; 2012; 35(2):125-30. PubMed ID: 22306900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
